David Segarnick
Biology graduate from Bard College, with MSc, PhD and Post-Doctoral Fellowship in Neuropharmacology from NYU. Currently working at Terravation LLC.
| Headline: | Entrepreneur |
| Interested in: | Brainstorming, Finding business partners, Finding cofounders, Finding team mates, Meeting new people, Professional opportunities, Promoting my startups, Recruiting for my startup |
| Schools: | Bard College, New York University |
WORK EXPERIENCE
| Employer: | Terravation LLC Medical Education |
| Position: | Strategic Consulting |
| Time period: | March 2008 - Present |
| Employer: | Impact Communications (a division of The Impact Group, NYC) |
| Position: | Chief Medical Officer/Managing Partner |
| Time period: | December 1995 - November 2008 |
| Description: | • Responsible for identification and development of more than 30 new clients exceeding $40 million in fee revenue over 6 years for medical education programs from GlaxoSmithkline, Merck, AstraZeneca, Lilly and Amgen
• Therapeutic areas included oncology, GI (GERD and IBS), diabetes, urology (OAB, ED), pain management, CNS (Parkinson’s disease, RLS, Bipolar disorder, migraine, epilepsy, ADHD, sleep disorder), interventional cardiology, oncology • Provided strategic medical/marketing direction for pre-launch and launch programs for blockbuster product launches |
| Employer: | Physicians World Communications Group, Secaucus, NJ |
| Position: | Vice President/Director Editorial & Medical |
| Time period: | December 1991 - November 1996 |
| Description: | • Responsible for development of 10 new accounts exceeding $10 million in fee
o Developed novel medical/marketing concepts that helped defined new product positioning across advertising, public relations and medical communications (eg, insulin sensitization to explain mechanism of action of thiazoledinediones (eg, Rezulin, Avandia) in Type 2 diabetes; nitric oxide/EDRF activity of mononitrates for angina) |
| Employer: | Wang Associates Health Communications, NYC |
| Position: | Senior Vice President, Director of Medical Communications |
| Time period: | December 1989 - November 1992 |
| Employer: | Manning, Selvage and Lee (Dmb&B), NYC |
| Position: | Vice President, Director for Science and Medical Affairs |
| Time period: | December 1986 - November 1990 |
| Employer: | NYU School of Medicine/Va Medical Center |
| Position: | Research Assistant Professor, Department of Pharmacology and Psychiatry |
| Time period: | December 1984 - November 1987 |
EDUCATION
| University: | New York University |
| Time period: | 1983 - 1985 |
| Degree: | Post-Doctoral Fellowship in Neuropharmacology |
| University: | New York University |
| Time period: | 1984 |
| Degree: | Pharmacology, PhD |
| University: | New York University |
| Time period: | 1981 |
| Degree: | Chemistry, MSc |
| University: | Bard College |
| Time period: | 1978 |
| Degree: | Biology, BA |
PUBLICATIONS
| Papers: | Segarnick, D.J., Traficante, L.J., Maple, W.T. Ferguson, J.B. Effects of Chronic Lithium Treatment on Concanavalin A Binding to Rat Striatal Membranes. Experientia, 35:655, 1979.
Rotrosen, J., Mandio Cordasco, D., Segarnick, D.J., Traficante, L.J., Gershon, S. Ethanol and Prostaglandin E1: Biochemical and Behavioral Interactions. Life Sciences, 26:1867, 1980. Mandio Cardasco, D., Segarnick, D.J., Rotrosen, J. Human Platelet Phospholipid Methylation. Life Sciences, 29:2299, 1981. Segarnick, D.J., Rotrosen, J., Mandio Cordasco, D. Biochemical and Behavioral Interactions Between Alcohol and Prostaglandin E1, in: Clinical Uses of Essential Fatty Acids, Eden Press, Montreal, D.F. Horrobin (ed.), p. 175-190, 1982. Serby, M., Segarnick, D.J., Mandio Cordasco, D., Rotrosen, J. Piracetam Reduces Alcohol Withdrawal in Mice Without Potentiating Alcohol Sedative Effects. Alcoholism: Clinical and Experimental Reserach, 6:4, 1982. Mandio Cordasco, D., Wazer, D., Segarnick, D.J., Lautin, A., Lippa A., Rotrosen, J. Phospholipids and Phospholipid Methylation in Platelets and Brain. Presented at the meeting of the American College of Neuropsychopharmacology, San Diego, California, November 1982. Psychopharmacology Bulletin, Vol 18, 1982. Lautin, A., Mandio Cordasco, D., Segarnick, D.J., Lippa, A., Meyerson, L.R., Benson, D., Rotrosen, J. Red Blood Cell Phospholipid Ratios in Schizophrenic and Control Populations. Life Sciences, 31:3051, 1982. Wazer, D. Mandio Cordasco, D., Segarnick, D.J., Wood, L., Mason, M., Rotrosen, J. Norepinephrine Stimulated Phospholipid Methylation in Rat Cerebral Cortices: Fact or Artifact? Life Sciences, 32:2535, 1983. Segarnick, D.J., Mandio Cordasco, D., Agura, V., Copper, N., Rotrosen, J., Gamma - Linolenic Acid Inhibits the Development of the Ethanol - Induced Fatty Liver. Prostaglandins Leukotrienes and Medicine, 17 (3):277, 1985. Segarnick, D.J., Mandio Cordasco, D. Rotrosen, J. Prostanoid Modulation (Mediation?) of Certain Behavioral Effects of Ethanol. Pharmacology, Biochemistry and Behavior, 23:71, 1985. Segarnick, D.J., Ryer, H., Rotrosen, J., Precursor - and Pool - Dependent Differential Effects of Ethanol on Human Platelet Prostanoid Synthesis. Biochemical Pharmacology, 34(8):1343, 1985. Rotrosen, J., Segarnick, D.J., Wolkin, A. Essential Fatty Acids and Prostaglandins as Drugs in the Treatment of Alcoholism in: Phospholipids in the Nervous System, Livina Press, Padova, Italy, L.A. Horrocks, G. Taffano and L. Freysz (eds.) 1986. Wolkin, A., Segarnick, D.J., Sierkierski, J., Mandu, M., Horrobin, D., Rotrosen, J. Essential Fatty Acid Supplementation During Early Alcohol Abstinence. Alcoholism: Clinical and Experimental Research, 11(1):87, 1987. Segarnick, D.J., Steroids, American Association of Occupational Health Nurses Journal, 35(6):286, 1987. Segarnick, D.J., Head Trauma and Psychiatric Illness: Is There A Connection? Journal of Psychosocial Nursing, 27(2):5, 1989. |
INFORMATION
| Hobbies: | • Concert classical and South American guitarist
• Black belt (2nd degree) in World Oyama full-contact karate |
| Memberships: | • American Association for the Advancement of Science
• New York Academy of Sciences • Drug Enforcement Administration (controlled substance registration) |
David's Startups (1)
View all-
TERRAVATION LLC
TERRAVATION LLC is a healthcare medical & marketing communictions firm that provides strategic planning and grant development to medical societies (eg, the American College of Cardiology), medical schools, government and medical educational agencies
David is Following (10)
View all-
Biolex Therapeutics
We are a clinical-stage biopharmaceutical company that uses our patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency.
-
Circassia
Circassia is developing targeted T-cell vaccines designed to treat allergies and prevent organ transplant rejection.
-
CoDa Therapeutics
CoDaTherapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair.
-
MedicalPlexus
An interactive web 2.0 professional network exclusively for physicians, researchers, and medical students to share clinical insights and user-generated content that may facilitate collaboration and advance medical knowledge.
David's Contacts (2)
View all-
Rade Glomazic
Currently a Doctoral candidate in Political science at the European Center for Peace and Development of the UN University of Peace. Have over ten years of professional experience working in socio-economic development activities and int. cooperation
-
